RZLT — Rezolute Inc
NASDAQ · Healthcare · Biotechnology
$4.50
-$0.19 (-4.05%)
Rezolute Inc (RZLT) is a biotechnology company listed on NASDAQ. It is led by Nevan Charles Elam J.D., based in 275 Shoreline Drive, Redwood City, CA, United States, 94065, with about 68 employees. Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Net income was -$18.1M. RZLT currently screens at market cap $461.2M.
Use this RZLT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RZLT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RZLT SEC filings page. Lician reads the product cache first so this HTML stays unique to Rezolute Inc even when a live quote feed is slow.
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Key Statistics
Market Cap
$461.24M
Volume
1.75M
Previous Close
$5.01
Day Range
$4.94 – $5.21
P/B Ratio
3.75
EPS
-$0.98
Revenue
$0.00
Net Income
-$74.41M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
68
RZLT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$74.41M | -$68.46M | -$51.79M |
| EPS (Diluted) | -$0.98 | -$1.33 | -$1.01 |
Total Assets
$175.49M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$94.11M
Operating Cash Flow
-$69.08M
Free Cash Flow
$0.00
Rezolute Inc Company Information
- Founder, CEO, Principal Financial Officer & Acting Chairman of the Board
- Nevan Charles Elam J.D.
- Headquarters
- 275 Shoreline Drive, Redwood City, CA, United States, 94065
- Website
- www.rezolutebio.com
- Phone
- 650 206 4507
- IPO / Founded
- 2014-05-01
- Sector
- Healthcare
- Industry
- Biotechnology